IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v43y2020i4d10.1007_s40264-019-00895-2.html
   My bibliography  Save this article

Patient-Reported Adverse Events of Radiopharmaceuticals: Development and Validation of a Questionnaire

Author

Listed:
  • Nanno Schreuder

    (Groningen Research Institute of Pharmacy, University of Groningen
    GE Healthcare Radiopharmacy Zwolle)

  • Quincy Hoog

    (Groningen Research Institute of Pharmacy, University of Groningen)

  • Sieta T. Vries

    (University of Groningen, University Medical Center Groningen)

  • Pieter L. Jager

    (Isala Hospital)

  • Jos G. W. Kosterink

    (Groningen Research Institute of Pharmacy, University of Groningen
    University of Groningen, University Medical Center Groningen)

  • Eugène P. Puijenbroek

    (Groningen Research Institute of Pharmacy, University of Groningen
    Netherlands Pharmacovigilance Centre Lareb)

Abstract

Introduction Radiopharmaceuticals may cause adverse events. Knowledge about adverse events from a patient’s perspective could help healthcare professionals to detect, understand, and manage adverse events more efficiently when using radiopharmaceuticals. Researchers need a validated questionnaire that can be used in patients to assess adverse events with radiopharmaceuticals. Objective The aim of this study was to develop, validate the content of, and perform initial testing of a questionnaire assessing patient-reported adverse events of radiopharmaceuticals. Methods Based on existing literature, six professionals drafted and evaluated a first version of the questionnaire. Further content validation was performed using cognitive interviews with six patients undergoing a nuclear medicine examination. After adaptations, the questionnaire was developed into a web-based questionnaire. One hundred patients undergoing nuclear examination tested this version, and the results were used to assess its acceptability and evaluate reported adverse events. Results Questions and answer options were revised in the initial questionnaire to improve clarity. In addition, some questions were removed. The final version consisted of 18 questions. In the test phase, the acceptability of the questionnaire was demonstrated (e.g. 79% of the patients who received the questionnaire completed it, and the median time to complete the questionnaire was 12 min for patients who reported an adverse event). Of the 100 patients (53% men, median age 64 years), 12 reported a total of 22 adverse events. One of these adverse events had a high causal association. Conclusion After validation and testing, the developed questionnaire to study patient-reported adverse events of radiopharmaceuticals is a suitable and valid instrument which can be used in future research.

Suggested Citation

  • Nanno Schreuder & Quincy Hoog & Sieta T. Vries & Pieter L. Jager & Jos G. W. Kosterink & Eugène P. Puijenbroek, 2020. "Patient-Reported Adverse Events of Radiopharmaceuticals: Development and Validation of a Questionnaire," Drug Safety, Springer, vol. 43(4), pages 319-328, April.
  • Handle: RePEc:spr:drugsa:v:43:y:2020:i:4:d:10.1007_s40264-019-00895-2
    DOI: 10.1007/s40264-019-00895-2
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-019-00895-2
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-019-00895-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:43:y:2020:i:4:d:10.1007_s40264-019-00895-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.